ESPERION Appoints Sheldon Koenig as Chief Operating Officer
December 15 2020 - 7:00AM
Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon
Koenig, a proven leader in the cardiovascular market, as chief
operating officer, effective today. Koenig will report directly to
Tim M. Mayleben, president and chief executive officer of Esperion.
Koenig joins the executive team of Esperion and will provide
vision, leadership, strategy and operations expertise to further
evolve Esperion into a commercial leader in cardiovascular
medicine, as well as a highly successful, efficiently operated
global company.
“Sheldon brings an incredible amount of relevant
experience to our company that will be familiar to all of our
stakeholders. His commercial knowledge and applied learnings in
directly correlated launches will be invaluable to us and we are
pleased to have him join Esperion,” said Tim M. Mayleben, president
and chief executive officer of Esperion. “Sheldon is the right
leader at the right time to navigate our company through the
opportunities that lie ahead of us as we continue a period of rapid
growth as a company in 2021 and beyond.”
Koenig is an accomplished leader in the cardiovascular space and
brings over 25 years of leadership roles to Esperion. Most
recently, he served as executive vice president and chief
commercial officer of Portola pharmaceuticals until it was acquired
by Alexion. At Portola, Koenig and his team delivered $130M+ in
Andexxa® sales in the first year of commercialization, making it
one of the top five most successful hospital launches in 30 years.
Prior to joining Portola, Koenig was senior vice president and head
of the cardiovascular franchise for Sanofi where he led U.S.
business operations and product launches in more than 20 countries.
Previously, he served as vice president and global brand leader for
the cardiovascular division of Merck & Co, Inc. where, for more
than 25 years, he took on roles of increasing responsibility within
the Company’s cardiovascular and thrombosis franchises and led
marketing for the launch of ezetimibe.
“Joining Esperion gives me the opportunity to make a meaningful
impact on an organization that has incredible potential to make a
difference in the lives of patients where currently marketed
medicines fall short,” said Koenig. “The company is in a unique
position to deliver with two recently approved and launched
medicines in a market that is neglected in terms of innovation and
where physicians and patients alike can benefit from additional
therapeutic options. I am excited to join Esperion at such an
exciting stage and apply the collective learnings from my
complementary experiences to help execute on the Esperion mission
of lipid management for everyone.”
Koenig will assume responsibility for the commercial team at
Esperion. As part of today’s announcement, Mark Glickman, chief
commercial officer, will leave Esperion, effective immediately. “I
want to thank Mark and recognize his contribution in building our
commercial function and laying the initial groundwork in which our
company can grow,” said Mayleben.
ESPERION Therapeutics
Through scientific and clinical excellence, and a deep
understanding of cholesterol biology, the experienced Lipid
Management Team at ESPERION is committed to developing new LDL-C
lowering medicines that will make a substantial impact on reducing
global cardiovascular disease, the leading cause of death around
the world. For more information, please visit www.esperion.com and
follow us on Twitter at www.twitter.com/EsperionInc.
CLEAR Cardiovascular Outcomes Trial
The effect of bempedoic acid on cardiovascular morbidity and
mortality has not been determined. ESPERION initiated a global
cardiovascular outcomes trial (CVOT) to assess the effects of
bempedoic acid on the occurrence of major cardiovascular events in
patients with, or at high risk for, cardiovascular disease (CVD)
who are only able to tolerate less than the lowest approved daily
starting dose of a statin and are considered “statin averse.” The
CVOT — known as CLEAR Cardiovascular Outcomes Trial — is an
event-driven, global, randomized, double-blind, placebo-controlled
study that completed enrollment in August 2019 of over 14,000
patients with hypercholesterolemia and high CVD risk at over 1,400
sites in 32 countries.
ESPERION Therapeutics’ Commitment to Patients with
Hyperlipidemia
High levels of LDL-C can lead to a build-up of fat and
cholesterol in and on artery walls (known as atherosclerosis),
potentially leading to cardiovascular events, including heart
attack and stroke. In the U.S., 96 million people, or more than 37
percent of the adult population, have elevated LDL-C. There are
approximately 18 million people in the U.S. living with elevated
levels of LDL-C despite taking maximally tolerated lipid-modifying
therapy — including individuals considered statin averse — leaving
them at high risk for cardiovascular events1. In the United States,
more than 50 percent of atherosclerotic cardiovascular disease
(ASCVD) patients and heterozygous familial hypercholesterolemia
(HeFH) patients who are not able to reach their guideline
recommended LDL-C levels with statins alone need less than a 40
percent reduction to reach their LDL-C threshold goal2.
ESPERION’s mission as the Lipid Management Company is to deliver
oral, once-daily medicines that complement existing oral drugs to
provide the additional LDL-C lowering that these patients need.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Esperion’s
commercialization plans for bempedoic acid tablet, its expectations
for the market for medicines to lower LDL-C and the impact of
bempedoic acid tablet in such market, including the commercial
launch and the market adoption of bempedoic acid tablet in the
United States and European Union. Any express or implied statements
contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause Esperion’s actual results to differ significantly from
those projected, including, without limitation, delays or failures
in Esperion’s clinical development and commercialization plans, or
approval of expanded indications, that existing cash resources may
be used more quickly than anticipated, the impact of COVID-19 on
our business, clinical activities and commercial development plans,
and the risks detailed in Esperion’s filings with the Securities
and Exchange Commission. Any forward-looking statements contained
in this press release speak only as of the date hereof, and
Esperion disclaims any obligation or undertaking to update or
revise any forward-looking statements contained in this press
release, other than to the extent required by law.
References(1) ESPERION market research on file:
research project interviewing 350 physicians. ESPERION
Therapeutics, Inc. Sept-Oct 2018.(2) Data on file: analysis of
NHANES database. ESPERION Therapeutics, Inc. 2018.
All registered trademarks are property of their respective
owners.
Contact:Ben
ChurchESPERIONbchurch@esperion.com734-864-6774
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024